Genevant CL1

• UNSPSC Description:

  Genevant CL1 is an ionizable lipid (lipid 10, pKa=6.3), and it can be used for mRNA lipid nanoparticle (LNP) vaccine delivery[1][2].

• Target Antigen:

  Liposome

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/genevant-cl1.html

• Purity:

  98.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CN(C)CCCCC(OC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)CCC/C=C\CCCCC)=O

• Molecular Weight:

  588.00

• References & Citations:

  [1]Michael D Buschmann, et al. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines (Basel). 2021 Jan 19;9(1):65.|[2]Lam K, Leung A, Martin A, et al. Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid-Nanoparticle Components for Therapeutic and Vaccine Applications. Adv Mater. 2023;35(15):e2209624.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1450888-71-7